Opinion|Videos|September 23, 2024
Utilizing Long-Term Atopic Dermatitis Data in Clinical Practice
Medical experts discuss long-term data for other systemic agents in atopic dermatitis and how this information informs their treatment decisions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Please share long-term data with other systemic agents in atopic dermatitis and how you use these data to make treatment decisions
Advertisement
Related to this article
For Eczema Awareness Month, Keira Barr, MD, explains the stress-itch cycle in atopic dermatitis and questions to uncover its hidden burden in clinic.
Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.
Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
Kidney Compass: ORIGIN 3 Final eGFR Data for Atacicept in IgA Nephropathy
4
FDA Approves Berotralstat Oral Pellets for Adults, Adolescents With HAE
5